Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing: Part 1, Considerations for Technology Transfer and Commercial Development

Publication
Article
BioPharm InternationalBioPharm International-10-01-2001
Volume 14
Issue 10

by Steven Ford and William E. Tente Chimeric Therapies, Inc. Manufacturing processes for murine monoclonal antibodies (mMABs) used in therapeutic applications must address more safety concerns than those used for in vitro diagnostics. Adequate characterization helps ensure that the mMAb retains its functional integrity after more extensive processing.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Mike Schaefers Simtra BioPharma Solutions, Shiva Khalafpour MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany
Chris Hagan, SCIEX
Daniel Fischer, Tevard
Junevity Co-founder & CEO, John Hoekman, PhD
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.